Genetic polymorphisms in the preprotachy kinin gene
OwnerDorothee Foernzler, Lara Hashimoto +4inventors
InventorsDorothee Foernzler, Lara Hashimoto, Jia Li, Eric Luedin, Andrew Sleight, Pierre Vankan
Life of this patent
Estimating the term…
Loading patent…
OwnerDorothee Foernzler, Lara Hashimoto +4inventors
InventorsDorothee Foernzler, Lara Hashimoto, Jia Li, Eric Luedin, Andrew Sleight, Pierre Vankan
Estimating the term…
The present invention relates to a method for correlating single nucleotide polymorphisms in the preprotachykinin (NKNA) gene with the efficacy and compatibility of a pharmaceutically active compound administered to a human being. The invention further relates to a method for determining the efficacy and compatibility of a pharmaceutically active compound administered to a human being which method comprises determining at least one single nucleotide polymorphism in the NKNA gene. Said methods are based on determining specific single nucleotide polymorphisms in the NKNA gene and determining the efficacy and compatibility of a pharmaceutically active compound in the human by reference to polymorphism in NKNA. The invention further relates to isolated nucleic acids comprising within their sequence the polymorphisms as defined herein, to nucleic acid primers and oligonucleotide probes capable of hybridizing to such nucleic acids and to a diagnostic kit comprising one or more of such primers and probes for detecting a polymorphism in the NKNA gene, to a pharmaceutical pack comprising NK-1 receptor antagonists and instructions for administration of the drug to human beings tested for the polymorphisms as well as to a computer readable medium with the stored sequence information for the polymorphisms in the NKNA gene.
A method for correlating single nucleotide polymorphisms in the NKNA gene with the efficacy and compatibility of a pharmaceutically active compound administered to a human being which method comprises determining single nucleotide polymorphisms in the NKNA gene of a human being and determining the status of said human being to which a pharmaceutically active compound was administered by reference to polymorphism in the NKNA gene.
A method for determining the efficacy and compatibility of a pharmaceutically active compound for a human being, which method comprises determining the presence of single nucleotide polymorphisms in the NKNA genomic sequence obtained from the human being which single nucleotide polymorphisms are correlated with the efficacy and compatibility of the pharmaceutically active compound, and thereby determining the efficacy and compatibility of the pharmaceutically active compound for the human being.
An isolated nucleic acid molecule selected from the group of:
An allele-specific nucleic acid primer capable of detecting a polymorphism in the NKNA gene at one or more of the positions 33612, 33949, 37025, 37114, 37434, 41112 and 41172 of the nucleotide sequence in FIG. 2.
An oligonucleotide probe for detecting a polymorphism in the NKNA gene capable of hybridizing specifically to a nucleic acid wherein the nucleotide polymorphism in the NKNA gene is selected from at least one of
A diagnostic kit comprising at least one of an allele-specific nucleic acid primer capable of detecting a polymorphism in the NKNA gene at one or more of the positions 33612, 33949, 37025, 37114, 37434, 41112 and 41172 of the nucleotide sequence in FIG. 2 and an oligonucleotide probe for detecting a polymorphism in the NKNA gene capable of hybridizing specifically to a nucleic acid wherein the nucleotide polymorphism in the NKNA gene is selected from at least one of
A pharmaceutical pack comprising NK-1 receptor antagonists and instructions for administration of the drug to human beings tested for a single nucleotide polymorphism at one or more positions of the NKNA gene.
A pharmaceutical pack comprising NK-1 receptor antagonists and instructions for administration of the drug to human beings tested for a single nucleotide polymorphism at one or more of the positions 33612, 33949, 37025, 37114, 37434, 41112 and 41172 of the nucleotide sequence in FIG. 2.
Method for treating a NK-1 receptor ligand-mediated disease in a human being diagnosed as having a single nucleotide polymorphism at one or more of position 33612, 33949, 37025, 37114, 37434, 41112 and 41172 of the nucleotide sequence in FIG. 2 comprising the NKNA gene comprising administrating to a patient in need thereof a pharmaceutically effective amount of a NK-1 receptor antagonist.
A computer readable medium having stored thereon sequence information for the polymorphisms in the NKNA gene comprising polymorphisms in at least one of the following positions:
Dependencies are inferred from the claim text.